222,844 Shares in Alto Neuroscience, Inc. $ANRO Acquired by Spruce Street Capital LP

Posted by Brenda Bartman on Jun 16th, 2026

Spruce Street Capital LP purchased a new position in Alto Neuroscience, Inc. (NYSE:ANRO – Free Report) during the 4th quarter, HoldingsChannel reports. The firm purchased 222,844 shares of the company’s stock, valued at approximately $3,967,000. Alto Neuroscience accounts for about 1.3% of Spruce Street Capital LP’s portfolio, making the stock its 21st largest holding.

Several other hedge funds have also made changes to their positions in ANRO. AQR Capital Management LLC bought a new stake in shares of Alto Neuroscience in the 1st quarter worth approximately $52,000. Torren Management LLC bought a new stake in shares of Alto Neuroscience in the 4th quarter worth approximately $62,000. Invesco Ltd. bought a new stake in shares of Alto Neuroscience in the 1st quarter worth approximately $67,000. Bridgeway Capital Management LLC lifted its holdings in shares of Alto Neuroscience by 85.9% in the 2nd quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock worth $119,000 after purchasing an additional 25,000 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of Alto Neuroscience in the 2nd quarter worth approximately $240,000.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Wedbush raised their price target on Alto Neuroscience from $21.00 to $24.00 and gave the stock a “neutral” rating in a report on Thursday, May 14th. JonesTrading lowered their target price on Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating on the stock in a research report on Thursday, April 2nd. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Alto Neuroscience in a research report on Wednesday, May 27th. Weiss Ratings upgraded Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 1st. Finally, Jefferies Financial Group restated a “buy” rating and issued a $35.00 target price on shares of Alto Neuroscience in a research report on Monday, March 16th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Alto Neuroscience has a consensus rating of “Moderate Buy” and a consensus target price of $35.25.

Read Our Latest Analysis on Alto Neuroscience

Alto Neuroscience Stock Down 1.6%

ANRO opened at $21.14 on Tuesday. Alto Neuroscience, Inc. has a 12 month low of $2.15 and a 12 month high of $28.44. The company has a debt-to-equity ratio of 0.07, a current ratio of 20.52 and a quick ratio of 20.52. The stock has a market cap of $741.63 million, a P/E ratio of -8.73 and a beta of 1.24. The stock’s 50 day moving average price is $22.71 and its 200 day moving average price is $19.61.

Alto Neuroscience (NYSE:ANRO – Get Free Report) last posted its earnings results on Wednesday, May 13th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.24). As a group, research analysts predict that Alto Neuroscience, Inc. will post -3.01 earnings per share for the current year.

Alto Neuroscience Company Profile

(Free Report)

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.